LRRK2 and Parkinson disease: Once PD is manifesting, patients with the LRRK2 G2019S mutation do not appear to have higher inflammatory cytokine levels than idiopathic patients (Dzamko et al., 2016; Ahmadi Rastegar et al., 2019).